Drake Highlights PARP Inhibitors, Immunotherapy in Prostate Cancer – OncLive
OncLive |
Drake Highlights PARP Inhibitors, Immunotherapy in Prostate Cancer
OncLive Immunotherapy in prostate cancer, however, has experienced a fair share of successes and disappointments. With a bevy of initial excitement surrounding this treatment option, enthusiasm has waned in much of the community. Yet, a future for … |
